Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Addressing a Public Health Crisis: Applications for COVID-19 Antibody Testing

Description: COVID-19 antibody testing plays a critical role in the public health response to this pandemic, including helping to determine prevalence of SARS-CoV-2 infection in the community or population of interest; providing information to assist in surveillance program efforts, and implement disease mitigation. During this presentation the presenters discuss commercial lab and public health collaborations, including current COVID-19 initiatives, explain the basis for serology tests for COVID-19 and recommendations for use, describe the utility of antibody testing in seroprevalence surveillance, and containment.

 

At the conclusion of this program, participants will be able to: 

  -  Discuss commercial lab and public health collaborations, including

     current COVID-19 initiatives 

  -  Explain the basis for serology tests for COVID-19 and recommendations

     for use 

  -  Describe the utility of antibody testing in seroprevalence surveillance

     and containment

Date:
Jul 27, 2020
Location:

 

  -  Hema Kapoor, MD SM, D(ABMM), Senior Medical Director

     Infectious Diseases & Immunology and Global Diagnostics

     Network, Quest Diagnostics, Secaucus, New Jersey  

 

  -  William A Meyer III,  PhD, D(ABMM), MLS(ASCP)CM, Director,

     Medical Science Liaison, Infectious Diseases/Immunology,

     Technical Director- Quest Diagnostics, East Region Baltimore,

     Maryland  

 

 -  Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice

    President, Research & Development and Medical, Quest

    Diagnostics, San Juan Capistrano, California 

Related content

Test FAQ
SARS CoV 2 Antibody Testing
Publication
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
New diagnosis of systemic lupus erythematosus after COVID-19 vaccination: A case report and review of literature
Publication
Changes in ganglioside antibody positivity rates during the COVID-19 pandemic
Publication
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022
Publication
Microfluidic immuno-serolomic assay reveals systems level association with COVID-19 pathology and vaccine protection

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.